Last updated: July 17, 2025

Why Medication Safety Matters

At Solari, your well‑being is our highest priority. GLP‑1 medications—whether FDA‑approved (like Ozempic®, Zepbound®) or compounded—have specific safety profiles. We’re transparent about their benefits and risks to ensure informed, safe treatment.

Ozempic® (semaglutide)

FDA-approved for: Type 2 diabetes

Warnings:

• May increase risk of thyroid C-cell tumors (animal data)
• Do not use if you or a family member has a history of MTC or MEN 2
• Not for use during pregnancy or while breastfeeding

Common side effects: Nausea, vomiting, diarrhea, constipation, fatigue, dizziness, injection site reactions

Notes:

• Slows digestion (can interfere with other medications)
• Must be taken weekly via subcutaneous injection
• Only to be used under supervision of a licensed provider

Zepbound® / Mounjaro® (tirzepatide)

FDA-approved for: Chronic weight management in adults with obesity or overweight (plus a comorbidity)

Warnings:

• Similar thyroid cancer risk warning as Ozempic
• May impact gallbladder and pancreas
• May reduce effectiveness of oral contraceptives
• Not for use in pregnancy or while breastfeeding

Common side effects: Nausea, vomiting, diarrhea, stomach pain, constipation, fatigue, injection site reactions

Notes:

• Higher rates of weight loss than semaglutide in some clinical trials
• Not to be used in combination with other GLP‑1 or GIP receptor agonists
• Administered weekly by injection

Compounded Tirzepatide

Not FDA-approved. Compounded tirzepatide is a version of the active ingredient in Zepbound®/Mounjaro®, prepared by a licensed pharmacy.

Risks:

• Not evaluated by the FDA for safety or effectiveness
• Formulations and potency may vary
• Must be dispensed by a state-licensed, compliant compounding pharmacy

Common side effects (similar to brand): Nausea, diarrhea, fatigue, slowed digestion, injection site reactions

Notes:

• Patients must disclose full medical history
• Risk of gallbladder issues, thyroid concerns, or pancreatitis
• Only prescribed when commercial options are unavailable or not appropriate

Compounded Semaglutide

Not FDA-approved. Compounded semaglutide is an alternative to Ozempic® or Wegovy®, prepared by a licensed compounding pharmacy.

Risks:

• Same safety warnings as Ozempic
• Not FDA-evaluated; quality depends on the pharmacy
• Greater risk of variability in dosing and ingredients

Common side effects (similar to brand): Nausea, vomiting, constipation, dizziness, headache, fatigue, injection site irritation

Notes:

• Inform your provider if you are taking other medications, pregnant, or planning surgery
• Strictly follow dosing and storage instructions
• Do not take with other GLP‑1 medications unless advised by your provider

General Safety Instructions

Before beginning treatment with any GLP‑1 medication:

• Disclose all current medications and medical conditions to your provider
• Do not use if you are pregnant or breastfeeding
• Store medications according to label and pharmacy instructions
• Never self-adjust your dose without medical supervision
• Report side effects to your provider or the FDA MedWatch program: www.fda.gov/medwatch

Disclaimer

Solari provides access to licensed healthcare providers who may prescribe GLP‑1 medications when clinically appropriate.

Ozempic is FDA-approved for diabetes, not weight loss. Compounded medications are not FDA-approved and may vary in quality.

All medications must be taken under the guidance of a licensed medical professional. Individual results vary.